Two safety concerns dominate patient questions about these medications: GLP-1 pancreatitis risk and thyroid cancer risk from the boxed warning. Both deserve accurate, calibrated counseling — neither dismissed nor exaggerated. Patients arrive having read alarming headlines, and a prescriber’s job is to explain what the evidence actually shows, screen appropriately, and document the conversation.
This guide walks through what the medullary thyroid carcinoma (MTC) boxed warning really means, how strong the pancreatitis signal is, how to take a focused history, what to monitor, and how to handle informed consent. It pairs closely with our GLP-1 contraindications and patient selection guide and the broader prescriber’s guide to GLP-1 medications for weight management.
Every GLP-1 receptor agonist carries a boxed warning about thyroid C-cell tumors, and understanding its basis is essential to counseling patients honestly. The warning originates from rodent studies in which GLP-1 agonists caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma, in rats and mice. Rodent C-cells express GLP-1 receptors far more densely than human C-cells do, which is the biological reason the finding may not translate — a point worth understanding alongside the drug’s broader mechanism of action.
The critical nuance is that whether this finding translates to humans is unknown. Human relevance has not been established, and a causal link between these drugs and MTC in people has not been demonstrated. What the warning does mandate is clear and absolute: these agents are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). That contraindication is class-wide, so it does not change with the agent you pick when you are choosing between tirzepatide and semaglutide. For everyone else, the honest framing is that the concern is based on animal data of uncertain human significance — a real reason to screen, not a reason to panic.
Since the July 2026 version of this guidance, the human evidence base has grown enough to quote at the bedside. The largest of these studies followed 145,410 GLP-1 users in Denmark, Norway and Sweden against 291,667 patients on DPP-4 inhibitors and found a thyroid cancer hazard ratio of 0.93, with a 95% confidence interval of 0.66 to 1.31 (Pasternak et al., 2024). An international multisite cohort published the following year reached the same conclusion across six databases (Baxter et al., 2025). The honest caveat is that the medullary subtype is rare enough that its own estimate — a hazard ratio of 1.19 with an interval running from 0.37 to 3.86 — cannot rule out a small increase in risk. That is the sentence to have ready when a well-read patient pushes back.
Pancreatitis is the risk patients most often fear, and here the gap between perception and evidence is wide. Acute pancreatitis has been reported in patients taking GLP-1 agonists, and it appears in the prescribing information as a warning — but the strength of the causal association is weaker than the headlines suggest.
Large cardiovascular outcome trials and their safety analyses have not demonstrated a clear, significant increase in pancreatitis attributable to these drugs (Lincoff et al., 2023; Marso et al., 2016). A living systematic review circulated in March 2026 pooled 31 placebo-controlled randomized trials covering 40,274 patients and 51,346 patient-years of active treatment, and found 59 pancreatitis events on GLP-1 therapy versus 50 on placebo — an odds ratio of 0.99 (95% CI 0.67–1.45). The tirzepatide-only estimate was higher at 1.55 but so imprecise (0.41–5.84) that it carries little weight either way.
| Evidence source | Population | What it found |
|---|---|---|
| Scandinavian cohort (BMJ, 2024) | 145,410 GLP-1 users vs. 291,667 on DPP-4 inhibitors | Thyroid cancer HR 0.93 (0.66–1.31); MTC HR 1.19 (0.37–3.86) |
| International multisite cohort (Thyroid, 2025) | Six population databases across several countries | No increased thyroid cancer risk detected |
| Pooled trial meta-analysis (2026 preprint) | 31 placebo-controlled trials, 40,274 patients | Acute pancreatitis OR 0.99 (0.67–1.45) |
| SELECT and SUSTAIN-6 (NEJM) | Cardiovascular outcome trials of semaglutide | No clear, significant excess of pancreatitis |
| Product labeling (rev. 02/2026) | All approved GLP-1 and GLP-1/GIP agents | Boxed warning retained; not studied in prior pancreatitis |
Confidence intervals are 95%. The 2026 pooled analysis was circulated as a preprint and had not completed peer review at the time of writing — useful for framing the size of the signal, not for quoting as settled guidance.
The signal exists and warrants vigilance, but the best available evidence is broadly reassuring rather than alarming. The practical counseling posture is balanced: acknowledge that pancreatitis is a recognized, uncommon risk; explain that large studies have not shown a strong causal link; and be clear about the plan — if severe, persistent abdominal pain develops, stop the drug and seek evaluation. That combination respects both the evidence and the patient’s concern. Because abdominal symptoms are so common on therapy, the real skill is separating the benign from the urgent, which is covered in detail in our playbook for managing GLP-1 GI side effects.
The UK’s Medicines and Healthcare products Regulatory Agency strengthened the acute pancreatitis warnings across GLP-1 and GLP-1/GIP receptor agonists, citing 1,296 Yellow Card pancreatitis reports received between 2007 and 2025. Prescribers are advised to stay alert for pancreatitis symptoms, which can be difficult to identify early, and to use these agents with caution in patients with a history of pancreatitis. A parallel MHRA and Genomics England study launched in 2025 is collecting saliva samples from patients hospitalized with suspected GLP-1-related pancreatitis to test whether genetic factors predict who is vulnerable. US labeling is unchanged, but expect patients to arrive having read the coverage.
Good counseling starts with a focused history that surfaces the genuine red flags. Before prescribing, screen specifically for a personal or family history of medullary thyroid carcinoma or MEN2 — the one finding that absolutely rules the medication out — and for a history of pancreatitis, which calls for a careful risk-benefit discussion rather than automatic exclusion.
Ask directly rather than relying on the patient to volunteer these details; a family history of a rare thyroid cancer is not something most people think to mention. A history of gallbladder disease is also worth noting, given the association between rapid weight loss and gallstones. This screening overlaps with the broader pre-prescribing assessment detailed in our contraindications guide, and doing it consistently is what makes the rest of the counseling credible — you are not raising these issues abstractly, but because you have actually checked.
On prior pancreatitis, quote the label rather than improvising. Both the semaglutide and tirzepatide prescribing information state that the drug has not been studied in patients with a history of pancreatitis and that it is unknown whether those patients are at higher risk. That is neither a green light nor a prohibition — it is the exact reason the decision has to be made explicitly, with the patient, and written down. A charted line reading “prior gallstone pancreatitis 2019, resolved; risks and alternatives discussed; patient elects to proceed” is defensible. Silence is not.
What you monitor — and what you deliberately do not — matters here. For thyroid risk, routine monitoring of serum calcitonin or thyroid ultrasound is not recommended for patients on GLP-1 therapy; the labels themselves call its value for early MTC detection uncertain, and in practice it generates false alarms and unnecessary procedures. The appropriate approach is symptom awareness, not lab surveillance.
Counsel patients on the warning symptoms to report, and be specific enough that they know what crosses the threshold for a phone call. The goal is a patient who knows the small number of symptoms that warrant contact, without living in fear of a medication that is, for the large majority, well tolerated.
| Tell the patient to report | What you are looking for | Your next step |
|---|---|---|
| Severe, persistent abdominal pain, often radiating to the back, sometimes with vomiting | Acute pancreatitis | Stop the drug, evaluate, check lipase; do not restart if confirmed |
| A lump or mass in the neck | Thyroid nodule or tumor (rare) | Examine and image the neck; refer to endocrinology |
| Persistent hoarseness | Thyroid or laryngeal involvement (rare) | Evaluate rather than attribute to a cold |
| Difficulty swallowing or shortness of breath | Mass effect (rare) | Prompt evaluation |
| Right-upper-quadrant pain, fever, or jaundice | Gallbladder disease during rapid weight loss | Imaging and surgical referral as indicated |
Thyroid symptoms are rare and should be framed that way to patients — the purpose of naming them is recognition, not alarm. Give the list verbally and in writing, and note in the chart that you did.
Because these are boxed-warning drugs, documentation is not optional — it is part of defensible prescribing. The record should show that you screened for the absolute and relative contraindications, that you discussed the boxed warning and the pancreatitis consideration in plain language, and that the patient understood and agreed to proceed.
Capture the specifics: the personal and family history you took, the symptom counseling you provided, and the patient’s informed agreement to long-term therapy. Good informed consent here is not a signature on a form so much as a documented conversation — one that protects the patient by ensuring they understand what to watch for, and protects you by showing the assessment was thorough. Making that conversation identical at every visit, for every provider in the practice, is a matter of protocol design rather than memory; our guide to building a medical weight loss program covers how to build the intake and consent steps into the workflow. Building this into a repeatable protocol is exactly what IAPAM’s GLP-1 safety and prescribing certification is designed to instill.
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
There is no demonstrated causal link in humans. The boxed warning is based on thyroid C-cell tumors seen in rodents, and human relevance is unknown. A Scandinavian cohort of 145,410 GLP-1 users found a hazard ratio of 0.93 (95% CI 0.66 to 1.31) for thyroid cancer, and an international multisite cohort published in 2025 found no increased risk either. The drugs remain contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, but for everyone else the concern rests on animal data of uncertain significance.
Pancreatitis is a recognized but uncommon risk, and randomized data have not shown a clear causal increase. A 2026 living meta-analysis of 31 placebo-controlled trials covering 40,274 patients found an odds ratio of 0.99 (95% CI 0.67 to 1.45). It warrants vigilance rather than alarm: patients should stop the drug and seek evaluation if severe, persistent abdominal pain develops.
No. The labels state that routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC, because it tends to produce false alarms and unnecessary procedures. Symptom awareness is the recommended approach.
Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. This is an absolute contraindication and applies to every agent in the class, which is why taking a family history is an essential screening step.
It is not an absolute contraindication, but it is not a routine decision either. The labels state plainly that these agents have not been studied in patients with a history of pancreatitis and that it is unknown whether such patients are at higher risk. In February 2026 the UK regulator strengthened its advice to use these agents with caution in that group. Document a specific risk-benefit discussion rather than prescribing by default.
Document that you screened for MTC/MEN2 and pancreatitis history, discussed the boxed warning and pancreatitis risk in plain language, provided symptom counseling, and obtained the patient’s informed agreement. Treat informed consent as a documented conversation, not just a form.
Counseling patients on GLP-1 pancreatitis and thyroid risk is an exercise in calibration: take the boxed warning seriously enough to screen for MTC and MEN2 absolutely, keep the pancreatitis risk in accurate proportion, skip low-value calcitonin surveillance in favor of symptom awareness, and document the conversation. Done well, it leaves patients informed and confident rather than frightened.
To build safety and counseling protocols with confidence, IAPAM’s GLP-1 certification training — backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews — gives you evidence-based clinical frameworks. Clinicians expanding a cash-pay practice often add aesthetic services alongside weight management; the same foundation supports Botox® training for nurse practitioners.
Explore GLP-1 Certification Training →
Disclaimer: This article is for informational and educational purposes only and does not constitute medical or prescribing advice. Always verify the current FDA-approved prescribing information for each agent and individualize screening, monitoring, and counseling for every patient.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.